On Wednesday flagged promising late-phase demo results for its new Cagrilinitide being overweight remedy, because the Danish pharmaceutical big seeks a following-technology substitute to its blockbuster Wegovy weight-loss drug. That said, Cagrilintide remains in Section II/III trials. Though the early data is exciting, it has not still been accredited for https://josephj048fqa5.glifeblog.com/profile